Pharmacokinetics and safety of oral levofloxacin in human immunodeficiency virus-infected individuals receiving concomitant zidovudine
Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit StumbleUpon Twitter current issue AAC About AAC Subscribers Authors Reviewers Advertisers Inquiries from the Press Permissions & Commercial Reprints ASM...
Saved in:
| Published in | Antimicrobial Agents and Chemotherapy Vol. 41; no. 8; pp. 1765 - 1769 |
|---|---|
| Main Authors | , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Washington, DC
American Society for Microbiology
01.08.1997
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 0066-4804 1098-6596 |
| DOI | 10.1128/AAC.41.8.1765 |
Cover
Loading…
| Abstract | Services
AAC
Citing Articles
Google Scholar
PubMed
Related Content
Social Bookmarking
CiteULike
Delicious
Digg
Facebook
Google+
Mendeley
Reddit
StumbleUpon
Twitter
current issue
AAC
About
AAC
Subscribers
Authors
Reviewers
Advertisers
Inquiries from the Press
Permissions & Commercial Reprints
ASM Journals Public Access Policy
AAC
RSS Feeds
1752 N Street N.W. • Washington DC 20036
202.737.3600 • 202.942.9355 fax • journals@asmusa.org
Print ISSN:
0066-4804
Online ISSN:
1098-6596
Copyright © 2014
by the
American Society for Microbiology.
For an alternate route to
AAC
.asm.org, visit:
AAC
|
|---|---|
| AbstractList | Services
AAC
Citing Articles
Google Scholar
PubMed
Related Content
Social Bookmarking
CiteULike
Delicious
Digg
Facebook
Google+
Mendeley
Reddit
StumbleUpon
Twitter
current issue
AAC
About
AAC
Subscribers
Authors
Reviewers
Advertisers
Inquiries from the Press
Permissions & Commercial Reprints
ASM Journals Public Access Policy
AAC
RSS Feeds
1752 N Street N.W. • Washington DC 20036
202.737.3600 • 202.942.9355 fax • journals@asmusa.org
Print ISSN:
0066-4804
Online ISSN:
1098-6596
Copyright © 2014
by the
American Society for Microbiology.
For an alternate route to
AAC
.asm.org, visit:
AAC
This phase I, double-blind, randomized, placebo-controlled, parallel-design study was conducted to evaluate the safety and pharmacokinetics of levofloxacin in human immunodeficiency virus (HIV)-infected subjects concomitantly receiving a stable regimen of zidovudine (AZT). Sixteen HIV-infected males with CD4-cell counts ranging from 100 to 550 and not experiencing significant AZT intolerance were enrolled. Subjects received levofloxacin (350 mg of levofloxacin hemihydrate) or a placebo (eight subjects per treatment group) as a single oral dose on day 1, multiple doses every 8 h from days 3 to 9, and a single dose on day 10. On days 1 and 10, an AZT dose (100 mg) was administered concurrently with the study drug. In between these doses, AZT was administered according to the regimen used by the subject prior to entering the study up to a maximum of 500 mg/day. Plasma levofloxacin concentrations were monitored for 36 h after levofloxacin dosing on day 1, immediately prior to the morning doses on days 3 to 9, and for 72 h after dosing on day 10. Plasma AZT concentrations were monitored on day 0 for baseline (for 6 h after the AZT dose) and for 4 h after the AZT doses on days 1 and 10. Levofloxacin was rapidly absorbed (time to maximum plasma concentration, approximately 1.0 h) and extensively distributed in the body with an apparent volume of distribution of approximately 104 liters (approximately 1.34 liters/kg). Steady-state conditions on day 10 were confirmed. Pharmacokinetic profiles of levofloxacin from single doses and multiple (three-times-daily) doses were similar, with a moderate accumulation (observed day 10-to-day 1 ratio of the maximum plasma concentration, approximately 185% versus expected 169%; for the corresponding ratio of the area under the concentration-time curve from 0 to 8 h [AUC(0-8)], the values were observed 217% versus expected 169%) at steady state. Mean average steady-state peak plasma concentration, plasma levofloxacin concentration at the end of the dosing interval, AUC(0-8), terminal half-life, and total body clearance were 7.06 microg/ml, 3.62 microg/ml, 37.4 microg x h/ml, 7.2 h, and 9.4 liters/h (0.12 liters/h/kg), respectively. Pharmacokinetic profiles of levofloxacin in HIV-infected patients did not appear to be affected by the concomitant administration of AZT; nor were AZT pharmacokinetics altered by levofloxacin. Oral administration of 350 mg of levofloxacin hemihydrate every 8 h appeared to be well tolerated by the subjects. There were no apparent differences in adverse events between the two treatment groups. There were no clinically significant changes from baseline in any laboratory parameter or vital sign following treatments observed in this study. The study results suggest that there is no need for levofloxacin dosage adjustment in HIV-seropositive subjects who concomitantly receive AZT. This phase 1, double-blind, randomized, placebo-controlled, parallel-design study was conducted to evaluate the safety and pharmacokinetics of levofloxacin in human immunodeficiency virus (HIV)-infected subjects concomitantly receiving a stable regimen of zidovudine (AZT). Sixteen HIV-infected males with CD4-cell counts ranging from 100 to 550 and not experiencing significant AZT intolerance were enrolled. Subjects received levofloxacin (350 mg of levofloxacin hemihydrate) or a placebo (eight subjects per treatment group) as a single oral dose on day 1, multiple doses every 8 h from days 3 to 9, and a single dose on day 10. On days 1 and 10, an AZT dose (100 mg) was administered concurrently with the study drug. In between these doses, AZT was administered according to the regimen used by the subject prior to entering the study up to a maximum of 500 mg/day. Plasma levofloxacin concentrations were monitored for 36 h after levofloxacin dosing on day 1, immediately prior to the morning doses on days 3 to 9, and for 72 h after dosing on day 10. Plasma AZT concentrations were monitored on day 0 for baseline (for 6 h after the AZT dose) and for 4 h after the AZT doses on days 1 and 10. Levofloxacin was rapidly absorbed (time to maximum plasma concentration, similar to 1.0 h) and extensively distributed in the body with an apparent volume of distribution of similar to 104 liters ( similar to 1.34 liters/kg). Steady-state conditions on day 10 were confirmed. Pharmacokinetic profiles of levofloxacin from single doses and multiple (three-times-daily) doses were similar, with a moderate accumulation (observed day 10-to-day 1 ratio of the maximum plasma concentration, similar to 185% versus expected 169%; for the corresponding ratio of the area under the concentration-time curve from 0 to 8 h [AUC sub(0-8)], the values were observed 217% versus expected 169%) at steady state. Mean average steady-state peak plasma concentration, plasma levofloxacin concentration at the end of the dosing interval, AUC sub(0-8), terminal half-life, and total body clearance were 7.06 mu g/ml, 3.62 mu g/ml, 37.4 mu g-h/ml, 7.2 h, and 9.4 liters/h (0.12 liters/h/kg), respectively. Pharmacokinetic profiles of levofloxacin in HIV-infected patients did not appear to be affected by the concomitant administration of AZT; nor were AZT pharmacokinetics altered by levofloxacin. Oral administration of 350 mg of levofloxacin hemihydrate every 8 h appeared to be well tolerated by the subjects. There were no apparent differences in adverse events between the two treatment groups. There were no clinically significant changes from baseline in any laboratory parameter or vital sign following treatments observed in this study. The study results suggest that there is no need for levofloxacin dosage adjustment in HIV-seropositive subjects who concomitantly receive AZT. This phase I, double-blind, randomized, placebo-controlled, parallel-design study was conducted to evaluate the safety and pharmacokinetics of levofloxacin in human immunodeficiency virus (HIV)-infected subjects concomitantly receiving a stable regimen of zidovudine (AZT). Sixteen HIV-infected males with CD4-cell counts ranging from 100 to 550 and not experiencing significant AZT intolerance were enrolled. Subjects received levofloxacin (350 mg of levofloxacin hemihydrate) or a placebo (eight subjects per treatment group) as a single oral dose on day 1, multiple doses every 8 h from days 3 to 9, and a single dose on day 10. On days 1 and 10, an AZT dose (100 mg) was administered concurrently with the study drug. In between these doses, AZT was administered according to the regimen used by the subject prior to entering the study up to a maximum of 500 mg/day. Plasma levofloxacin concentrations were monitored for 36 h after levofloxacin dosing on day 1, immediately prior to the morning doses on days 3 to 9, and for 72 h after dosing on day 10. Plasma AZT concentrations were monitored on day 0 for baseline (for 6 h after the AZT dose) and for 4 h after the AZT doses on days 1 and 10. Levofloxacin was rapidly absorbed (time to maximum plasma concentration, approximately 1.0 h) and extensively distributed in the body with an apparent volume of distribution of approximately 104 liters (approximately 1.34 liters/kg). Steady-state conditions on day 10 were confirmed. Pharmacokinetic profiles of levofloxacin from single doses and multiple (three-times-daily) doses were similar, with a moderate accumulation (observed day 10-to-day 1 ratio of the maximum plasma concentration, approximately 185% versus expected 169%; for the corresponding ratio of the area under the concentration-time curve from 0 to 8 h [AUC(0-8)], the values were observed 217% versus expected 169%) at steady state. Mean average steady-state peak plasma concentration, plasma levofloxacin concentration at the end of the dosing interval, AUC(0-8), terminal half-life, and total body clearance were 7.06 microg/ml, 3.62 microg/ml, 37.4 microg x h/ml, 7.2 h, and 9.4 liters/h (0.12 liters/h/kg), respectively. Pharmacokinetic profiles of levofloxacin in HIV-infected patients did not appear to be affected by the concomitant administration of AZT; nor were AZT pharmacokinetics altered by levofloxacin. Oral administration of 350 mg of levofloxacin hemihydrate every 8 h appeared to be well tolerated by the subjects. There were no apparent differences in adverse events between the two treatment groups. There were no clinically significant changes from baseline in any laboratory parameter or vital sign following treatments observed in this study. The study results suggest that there is no need for levofloxacin dosage adjustment in HIV-seropositive subjects who concomitantly receive AZT.This phase I, double-blind, randomized, placebo-controlled, parallel-design study was conducted to evaluate the safety and pharmacokinetics of levofloxacin in human immunodeficiency virus (HIV)-infected subjects concomitantly receiving a stable regimen of zidovudine (AZT). Sixteen HIV-infected males with CD4-cell counts ranging from 100 to 550 and not experiencing significant AZT intolerance were enrolled. Subjects received levofloxacin (350 mg of levofloxacin hemihydrate) or a placebo (eight subjects per treatment group) as a single oral dose on day 1, multiple doses every 8 h from days 3 to 9, and a single dose on day 10. On days 1 and 10, an AZT dose (100 mg) was administered concurrently with the study drug. In between these doses, AZT was administered according to the regimen used by the subject prior to entering the study up to a maximum of 500 mg/day. Plasma levofloxacin concentrations were monitored for 36 h after levofloxacin dosing on day 1, immediately prior to the morning doses on days 3 to 9, and for 72 h after dosing on day 10. Plasma AZT concentrations were monitored on day 0 for baseline (for 6 h after the AZT dose) and for 4 h after the AZT doses on days 1 and 10. Levofloxacin was rapidly absorbed (time to maximum plasma concentration, approximately 1.0 h) and extensively distributed in the body with an apparent volume of distribution of approximately 104 liters (approximately 1.34 liters/kg). Steady-state conditions on day 10 were confirmed. Pharmacokinetic profiles of levofloxacin from single doses and multiple (three-times-daily) doses were similar, with a moderate accumulation (observed day 10-to-day 1 ratio of the maximum plasma concentration, approximately 185% versus expected 169%; for the corresponding ratio of the area under the concentration-time curve from 0 to 8 h [AUC(0-8)], the values were observed 217% versus expected 169%) at steady state. Mean average steady-state peak plasma concentration, plasma levofloxacin concentration at the end of the dosing interval, AUC(0-8), terminal half-life, and total body clearance were 7.06 microg/ml, 3.62 microg/ml, 37.4 microg x h/ml, 7.2 h, and 9.4 liters/h (0.12 liters/h/kg), respectively. Pharmacokinetic profiles of levofloxacin in HIV-infected patients did not appear to be affected by the concomitant administration of AZT; nor were AZT pharmacokinetics altered by levofloxacin. Oral administration of 350 mg of levofloxacin hemihydrate every 8 h appeared to be well tolerated by the subjects. There were no apparent differences in adverse events between the two treatment groups. There were no clinically significant changes from baseline in any laboratory parameter or vital sign following treatments observed in this study. The study results suggest that there is no need for levofloxacin dosage adjustment in HIV-seropositive subjects who concomitantly receive AZT. |
| Author | S C Chien R R Williams A T Chow M C Rogge C W Hendrix |
| AuthorAffiliation | The R.W. Johnson Pharmaceutical Research Institute, Raritan, New Jersey 08869, USA |
| AuthorAffiliation_xml | – name: The R.W. Johnson Pharmaceutical Research Institute, Raritan, New Jersey 08869, USA |
| Author_xml | – sequence: 1 givenname: S C surname: Chien fullname: Chien, S C organization: The R.W. Johnson Pharmaceutical Research Institute, Raritan, New Jersey 08869, USA – sequence: 2 givenname: A T surname: Chow fullname: Chow, A T organization: The R.W. Johnson Pharmaceutical Research Institute, Raritan, New Jersey 08869, USA – sequence: 3 givenname: M C surname: Rogge fullname: Rogge, M C organization: The R.W. Johnson Pharmaceutical Research Institute, Raritan, New Jersey 08869, USA – sequence: 4 givenname: R R surname: Williams fullname: Williams, R R organization: The R.W. Johnson Pharmaceutical Research Institute, Raritan, New Jersey 08869, USA – sequence: 5 givenname: C W surname: Hendrix fullname: Hendrix, C W organization: The R.W. Johnson Pharmaceutical Research Institute, Raritan, New Jersey 08869, USA |
| BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=2784965$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/9257757$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkU2LFDEQhoOsrLOrR49CC-JB6DHpTtLJYQ_D4Bcs6EHPIZ2uzGTtTtaku3X8Af5uM84wrMIiBJKinqp6K-8FOvPBA0JPCV4SUonXq9V6SclSLEnD2QO0IFiKkjPJz9ACY85LKjB9hC5SusE5ZhKfo3NZsaZhzQL9-rTVcdAmfHUeRmdSoX1XJG1h3BXBFiHqvuhhDrYPP7RxvshnOw06P4Zh8qED64wDb3bF7OKUSuctmBG6DHZudt2k-1REMJADvylM8CYMbtR-LH66LsxTlyc_Rg9t5uDJ8b5EX96--bx-X15_fPdhvbouNauasawoJhJrzoWmtWQdaYA0xBBsCZeCty0VkPeyEstKAGOWdG0DFaGtsEBbXF-iq0Pf26kdoDPgx7yguo1u0HGngnbq74x3W7UJsyKcYkxy_ctjfQzfJkijGlwy0PfaQ5iSaiSRdZb3X5DwitUV2yt6dQB1Gip1E6bo8wcogtXeXZXdVZQoofbuZvjZXfkn3Uc7c_7FMa-T0b2N2huXTljVCCr_tCkPmIkhpQj2RNw3tv6HN9nA0YX9H7n-3qrnh6qt22y_uwgqr6i0NneY3ynW3Hk |
| CODEN | AACHAX |
| CitedBy_id | crossref_primary_10_1128_AAC_47_5_1604_1613_2003 crossref_primary_10_1007_s11095_021_02994_1 crossref_primary_10_2165_00003088_200544060_00004 crossref_primary_10_1128_AAC_43_9_2323 crossref_primary_10_3390_separations10020136 crossref_primary_10_1007_s11259_007_0090_8 crossref_primary_10_1128_AAC_43_12_3005 crossref_primary_10_2165_00002018_200124030_00004 crossref_primary_10_1093_jac_dkaa328 crossref_primary_10_1592_phco_21_16_233S_33992 crossref_primary_10_1016_S0149_2918_98_80104_5 crossref_primary_10_1128_AAC_45_7_2160_2162_2001 crossref_primary_10_1016_j_tube_2015_02_037 crossref_primary_10_1592_phco_21_16_253S_33993 crossref_primary_10_1345_aph_17178 |
| ContentType | Journal Article |
| Copyright | 1997 INIST-CNRS |
| Copyright_xml | – notice: 1997 INIST-CNRS |
| DBID | AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7T2 7U9 C1K H94 7X8 5PM |
| DOI | 10.1128/AAC.41.8.1765 |
| DatabaseName | CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Health and Safety Science Abstracts (Full archive) Virology and AIDS Abstracts Environmental Sciences and Pollution Management AIDS and Cancer Research Abstracts MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) AIDS and Cancer Research Abstracts Health & Safety Science Abstracts Virology and AIDS Abstracts Environmental Sciences and Pollution Management MEDLINE - Academic |
| DatabaseTitleList | CrossRef AIDS and Cancer Research Abstracts MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Pharmacy, Therapeutics, & Pharmacology Biology |
| EISSN | 1098-6596 |
| EndPage | 1769 |
| ExternalDocumentID | PMC164001 10.1128/AAC.41.8.1765 9257757 2784965 10_1128_AAC_41_8_1765 aac_41_8_1765 |
| Genre | Clinical Trial, Phase I Clinical Trial Randomized Controlled Trial Journal Article |
| GroupedDBID | --- .55 .GJ 0R~ 23M 2WC 39C 3O- 4.4 53G 5GY 5RE 5VS 6J9 AAGFI AAYXX ACGFO ADBBV AENEX AGNAY AGVNZ AI. ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BTFSW C1A CITATION CS3 DIK E3Z EBS EJD F5P FRP GX1 H13 HH5 HYE HZ~ H~9 J5H K-O KQ8 L7B LSO MVM NEJ O9- OK1 P2P RHI RNS RPM RSF TR2 UHB VH1 W2D W8F WH7 WHG WOQ X7M X7N XOL Y6R ZGI ZXP ~A~ IQODW CGR CUY CVF ECM EIF NPM RHF - 08R 0R 55 A AAPBV ABFLS ADACO ADBIT AFMIJ BXI GJ HZ ZA5 7T2 7U9 C1K H94 7X8 5PM |
| ID | FETCH-LOGICAL-a527t-240190a668a4395d17e171c10f16986bb48e775f90928e55f1db7e214b8fe4b03 |
| ISSN | 0066-4804 |
| IngestDate | Thu Aug 21 14:10:10 EDT 2025 Thu Sep 04 21:30:22 EDT 2025 Fri Sep 05 01:08:01 EDT 2025 Tue Dec 28 13:58:51 EST 2021 Sat Sep 28 07:38:35 EDT 2024 Mon Jul 21 09:15:43 EDT 2025 Thu Apr 24 22:50:12 EDT 2025 Tue Jul 01 04:32:50 EDT 2025 Wed May 18 15:36:31 EDT 2016 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 8 |
| Keywords | Levofloxacin Toxicity Fluoroquinolone derivatives Randomization Lentivirinae Antiviral Drug interaction Pyrimidine nucleoside Quinolone derivatives Human Immunopathology Drug combination Oral administration Retroviridae AIDS Immune deficiency Infection Virus Viral disease Phase I trial Double blind study Human immunodeficiency virus Antibacterial agent Pharmacokinetics Zidovudine |
| Language | English |
| License | CC BY 4.0 |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-a527t-240190a668a4395d17e171c10f16986bb48e775f90928e55f1db7e214b8fe4b03 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 ObjectType-Undefined-3 |
| OpenAccessLink | https://aac.asm.org/content/aac/41/8/1765.full.pdf |
| PMID | 9257757 |
| PQID | 16253250 |
| PQPubID | 23462 |
| PageCount | 5 |
| ParticipantIDs | pascalfrancis_primary_2784965 pubmed_primary_9257757 pubmedcentral_primary_oai_pubmedcentral_nih_gov_164001 crossref_citationtrail_10_1128_AAC_41_8_1765 asm2_journals_10_1128_AAC_41_8_1765 proquest_miscellaneous_79193668 crossref_primary_10_1128_AAC_41_8_1765 proquest_miscellaneous_16253250 highwire_asm_aac_41_8_1765 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 1900 |
| PublicationDate | 1997-08-01 |
| PublicationDateYYYYMMDD | 1997-08-01 |
| PublicationDate_xml | – month: 08 year: 1997 text: 1997-08-01 day: 01 |
| PublicationDecade | 1990 |
| PublicationPlace | Washington, DC |
| PublicationPlace_xml | – name: Washington, DC – name: United States |
| PublicationTitle | Antimicrobial Agents and Chemotherapy |
| PublicationTitleAbbrev | Antimicrob Agents Chemother |
| PublicationTitleAlternate | Antimicrob Agents Chemother |
| PublicationYear | 1997 |
| Publisher | American Society for Microbiology |
| Publisher_xml | – name: American Society for Microbiology |
| References | 8363378 - Antimicrob Agents Chemother. 1993 Jul;37(7):1468-72 8031049 - Antimicrob Agents Chemother. 1994 Apr;38(4):799-804 1503449 - Antimicrob Agents Chemother. 1992 Apr;36(4):860-6 2174762 - Chemotherapy. 1990;36(4):268-76 3195996 - Antimicrob Agents Chemother. 1988 Sep;32(9):1336-40 |
| References_xml | – reference: 1503449 - Antimicrob Agents Chemother. 1992 Apr;36(4):860-6 – reference: 3195996 - Antimicrob Agents Chemother. 1988 Sep;32(9):1336-40 – reference: 2174762 - Chemotherapy. 1990;36(4):268-76 – reference: 8363378 - Antimicrob Agents Chemother. 1993 Jul;37(7):1468-72 – reference: 8031049 - Antimicrob Agents Chemother. 1994 Apr;38(4):799-804 |
| SSID | ssj0006590 |
| Score | 1.6826382 |
| Snippet | Services
AAC
Citing Articles
Google Scholar
PubMed
Related Content
Social Bookmarking
CiteULike
Delicious
Digg
Facebook
Google+
Mendeley
Reddit
StumbleUpon... This phase I, double-blind, randomized, placebo-controlled, parallel-design study was conducted to evaluate the safety and pharmacokinetics of levofloxacin in... This phase 1, double-blind, randomized, placebo-controlled, parallel-design study was conducted to evaluate the safety and pharmacokinetics of levofloxacin in... |
| SourceID | pubmedcentral proquest asm2 pubmed pascalfrancis crossref highwire |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 1765 |
| SubjectTerms | Adult Anti-HIV Agents Anti-HIV Agents - blood Anti-HIV Agents - pharmacokinetics Anti-HIV Agents - therapeutic use Anti-Infective Agents Anti-Infective Agents - adverse effects Anti-Infective Agents - blood Anti-Infective Agents - pharmacokinetics Antibacterial agents Antibiotics. Antiinfectious agents. Antiparasitic agents Biological and medical sciences Clinical Trial Clinical Trial, Phase I Double-Blind Method Drug Interactions HIV Infections HIV Infections - drug therapy HIV Infections - metabolism Humans Levofloxacin Male Medical sciences Ofloxacin Ofloxacin - administration & dosage Ofloxacin - adverse effects Ofloxacin - blood Ofloxacin - pharmacokinetics Pharmacology. Drug treatments Randomized Controlled Trial Zidovudine Zidovudine - blood Zidovudine - pharmacokinetics Zidovudine - therapeutic use |
| Title | Pharmacokinetics and safety of oral levofloxacin in human immunodeficiency virus-infected individuals receiving concomitant zidovudine |
| URI | http://aac.asm.org/content/41/8/1765.abstract https://www.ncbi.nlm.nih.gov/pubmed/9257757 https://journals.asm.org/doi/10.1128/AAC.41.8.1765 https://www.proquest.com/docview/16253250 https://www.proquest.com/docview/79193668 https://pubmed.ncbi.nlm.nih.gov/PMC164001 |
| Volume | 41 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLZgCMQLgsJEBwNLoL7QlDpNHOexqjZNaBsTtFLfIidx1og2QetFdD-A383xJbeyiktVVVVsuUnP5-Nz7HO-g9D7CGDCQjexSBz2LcenkeXbcWz5noDVlpPYVsHjF5f0bOJ8mrrT2ompzC5Zhb3o9s68kv-RKlwDucos2X-QbDkoXIDvIF_4BAnD51_J-MrwTn8DU7GkW17yROgwC5V8PxebPJnnP3iUqqBGXZQvlWkheSwkf4RKvtykN-ulpUOzhORjKvK05LFCJNKNTs7N4DFSWXj4w20a55t1XBzLl3zMq3SRKnInSUJwrfLnVOrcTCxMsle5iT-apVrpfa32akczQwlZRW9_ya9N_feqW2ObyAQ9xiaZzysj50p9TKnlMF2AuNDHDqnhjtWUK_F0WYnftb4tMxmGw1HPIT3WK_o12bUvPwenk_PzYHwyHd9HD2xwK_pKkVfuEnX1nlxxVwUnq80-NgaH5ZsvF3bTlCnopWV0LV_CBEt0ZZS7XJfdCNyaSTN-ip4YXwQPNbCeoXsia6GHujrptoUeXZi4ixbqGKRtu3hcJewtu7iDryru8-1z9HMXkhiEjzUkcZ5gCUlchySGt4Ik3oUkbkIS1yCJS0jiGiRxBckXaHJ6Mh6dWabUh8Vd21vJMz6wTDmljIOF7MbEE8QjEeknhPqMhqHDhOe5id_3bSZcNyGSFhz0SMgS4YT9wSE6yPJMvESYgmRdP4oisI0dHg9YLEOZeSip7BJ4tdE7KbzAzONloNxgmwUg4sAhAQukiNuoW8g2iAxbvizaMt_XvVN2_65pYvZ1PCqAEsBtBJxH9cbjBnTKoWR0gC_b3xZQCmAVkEd7PBP5Gp6B2u4AvJn9PTwfXDX4f9voUEOvHNyHVdtzvTaiDUyW7ZKAvtmSpTNFRE8oWADk6I-_-Qo9rmb_a3SwulmLY7DlV-EbNQF_AYv5-0g |
| linkProvider | ABC ChemistRy |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Pharmacokinetics+and+safety+of+oral+levofloxacin+in+human+immunodeficiency+virus-infected+individuals+receiving+concomitant+zidovudine&rft.jtitle=Antimicrobial+agents+and+chemotherapy&rft.au=Chien%2C+S+C&rft.au=Chow%2C+A+T&rft.au=Rogge%2C+M+C&rft.au=Williams%2C+R+R&rft.date=1997-08-01&rft.issn=0066-4804&rft.volume=41&rft.issue=8&rft.spage=1765&rft_id=info:doi/10.1128%2FAAC.41.8.1765&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0066-4804&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0066-4804&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0066-4804&client=summon |